Human umbilical cord blood stem cells, myocardial infarction and stroke.
Myocardial infarction (MI) and stroke are the first and third leading causes of death in the U.S.A. accounting for more than 1 in 3 deaths per annum. Despite interventional and pharmaceutical advances, the number of people diagnosed with heart disease is on the rise. Therefore, new clinical strategies are needed. Cell-based therapy holds great promise for treatment of these diseases and is currently under extensive preclinical as well as clinical trials. The source and types of stem cells for these clinical applications are questions of great interest. Human umbilical cord blood (hUCB) appears to be a logical candidate as a source of cells. hUCB is readily available, and presents little ethical challenges. Stem cells derived from hUCB are multipotent and immunologically naive. Here is a critical literature review of the beneficial effects of hUCB cell therapy in preclinical trials.
Copeland
Nathan
N
University of Arizona Medical School, Tucson, Arizona, USA.
Harris
David
D
Gaballa
Mohamed A
MA
D000818:Animals; D002423:Cause of Death / Q000639:trends; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000601:surgery*; D020521:Stroke / Q000401:mortality / Q000601:surgery*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology